接受司库奇尤单抗治疗的银屑病关节炎患者接种季节性流感疫苗的免疫原性与安全性
研究评估接受司库奇尤单抗≥3个月的银屑病关节炎患者与健康对照接种含3种抗原(H3N3、H1N1、B)的赛诺菲巴斯德流感疫苗后的免疫原性与安全性。两组各抗原几何平均滴度均显著升高,H3N2和H1N1应答者数量相似,B/Brisbane株在银屑病关节炎组显著更高,两组血清保护比例高且相似,未见疾病加重或严重不良反应。结论认为司库奇尤单抗治疗不影响银屑病关节炎患者对流感疫苗的体液应答。
要点
- 银屑病关节炎患者接种流感疫苗后各抗原几何平均滴度显著升高。
- H3N2和H1N1应答者数量两组相似,B/Brisbane株在银屑病关节炎组显著更高。
- 两组血清保护比例高且相似,未观察到疾病加重或严重不良反应。
核心结论
- 司库奇尤单抗治疗不影响银屑病关节炎患者对流感疫苗的体液应答。
研究设计与样本
- 研究纳入接受司库奇尤单抗≥3个月的连续32例银屑病关节炎患者为研究组,其中10例联用传统合成改善病情抗风湿药(多为甲氨蝶呤)。
- 对照组为17例年龄和性别匹配的健康对照(中位年龄48.5岁,6例女性)。
- 两组均接种赛诺菲巴斯德生产的含3种抗原(H3N3、H1N1和B)的疫苗,并在接种当天及4-6周后进行临床和实验室评估。
- 采用血凝抑制试验评估疫苗针对3种抗原的免疫原性。
- 各抗原应答者定义为抗原滴度升高4倍,或基线水平<1/40者发生血清转换。
主要发现
- 两组各抗原的几何平均滴度均显著升高。
- H3N2和H1N1的应答者数量在两组间相似,B/Brisbane的应答者数量在银屑病关节炎组显著更高。
- 血清保护水平(滴度>1/40)的比例在两组均高且相似。
- 应答率与年龄、性别或所选疾病活动度参数(压痛/肿胀关节计数、Leeds附着点炎指数、医生和患者整体评估、银屑病面积严重指数和C反应蛋白)无相关性。
- 接种后未观察到疾病加重,研究期间两组均未观察到严重不良反应。
关键数值与推荐
- 应答者定义为抗原滴度升高4倍或基线<1/40者发生血清转换。
- 血清保护水平定义为滴度>1/40。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the immunogenicity and safety of vaccination against seasonal influenza in psoriatic arthritis (PsA) patients treated with secukinumab versus healthy controls (HC). METHODS: PsA patients administered secukinumab for ≥3 months and HC received the Sanofi Pasteur vaccine composed of 3 antigens (H3N3, H1N1, and B) and underwent clinical and laboratory assessments on the day of vaccination and 4-6 weeks later. Immunogenicity of the vaccine was evaluated by hemagglutination inhibition assay against those 3 antigens. Responders to each antigen were defined by a 4-fold increase in the antigen titer or by seroconversion in patients whose baseline level was <1/40. RESULTS: Thirty-two consecutive PsA patients treated with secukinumab for ≥3 months comprised the study group, 10 of whom received concomitant conventional synthetic disease-modifying drugs, mostly methotrexate. There were 17 age- and gender-matched HC (median age 48.5 years, 6 females). The geometric mean titers of each antigen increased significantly in both groups. The number of responders in each group was similar for H3N2 and H1N1, and significantly higher for B/Brisbane in the PsA group. The proportion of patients with a seroprotective level (a titer >1/40) was high and similar in both groups. There was no correlation between the response rate and age, gender, or selected parameters of disease activity (tender/swollen joint counts, Leeds enthesitis index, physician and patient global assessment, psoriasis area severity index, and C-reactive protein). No disease exacerbation was observed following the vaccination. No serious adverse effects were observed in both groups during the study period. CONCLUSION: Secukinumab treatment does not affect the humoral response to influenza vaccine of patients with PsA.
引用
- Furer V, Zisman D, Kaufman I, et al. Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic arthritis treated with secukinumab. Vaccine. 2019. PMID: 31767465. doi:10.1016/j.vaccine.2019.10.081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。